Platform
Company
Coagulation
Review status
Currently under review
Pending specialist review and validation.
This test measures the functional activity of factor VIII, an essential blood protein that helps your blood form stable clots. It evaluates how well factor VIII in your plasma works within the clotting cascade rather than simply measuring how much of the protein is present. The notation in the test name refers to a standard dilution used during the laboratory method to ensure accurate measurement.
Your clinician may order this test to investigate bleeding symptoms, follow up on an abnormal clotting screen, or to monitor therapy that affects factor VIII. It is often performed alongside other coagulation tests to give a complete picture of your clotting system.
Low factor VIII activity can indicate hemophilia A or an acquired problem where your immune system develops an inhibitor that blocks factor VIII. Activity can also be reduced in some liver conditions or widespread clotting disturbances. Higher activity can be seen with inflammation, stress, pregnancy, or estrogen exposure, and is associated with a higher tendency to form clots.
Clinicians use this test to help diagnose and classify hemophilia A, to monitor response to factor replacement or desmopressin, and to check for inhibitors when results do not behave as expected on mixing studies. It can also help evaluate unexplained bleeding or an abnormal screening clotting result.
Your healthcare provider will interpret your result in the context of your symptoms, history, and other tests. If activity appears lower than expected, the team may repeat the test, confirm proper sample handling, and consider related testing such as von Willebrand factor studies, a mixing study, and an inhibitor assay. Treatment decisions are based on your overall situation, not a single laboratory value.
If activity appears higher than expected, your provider will consider factors such as recent illness, pregnancy, hormone therapy, or other clotting risk factors. If you are receiving factor concentrate or desmopressin, the timing of your blood draw relative to dosing is important for interpreting results. Tell your care team about all medicines and supplements, including anticoagulants, because some drugs can interfere with clot-based assays and may prompt use of an alternative testing method.
Reference intervals vary by laboratory, analyzer, methodology, population, and units. The ranges shown here are for education only. Always interpret your results against the reference interval printed on your own lab report.
Infusions of factor VIII concentrate or treatment with desmopressin can raise activity for a period of time. Coordinate testing with your care team, and when monitoring therapy, draw blood at the agreed time point, often before the next dose.
Heparin and some direct oral anticoagulants can affect clot-based assays and may lead to misleading results. Always inform your clinician and the lab about these medications so they can interpret results correctly or use alternative methods.
Factor VIII behaves as an acute phase protein, so levels can increase with infection, inflammation, stress, or after surgery. When possible, testing performed when you are well provides a truer baseline.
Pregnancy and estrogen-containing medications can increase factor VIII activity. Your provider will interpret results with this in mind, especially when evaluating clotting risk.
Underfilled citrate tubes, high hematocrit, prolonged tourniquet time, or delayed processing can alter results. Proper collection and prompt processing help ensure accuracy.
Specific factor VIII inhibitors or other antibodies can lower measured activity, and some conditions like von Willebrand disease can secondarily reduce factor VIII. Additional tests such as a mixing study or inhibitor assay may be needed.
References